This review summarizes a range of ADCs targeting tumor-associated antigens in ovarian cancer, including mirvetuximab soravtansine (MIRV), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), sacituzumab tirumotecan (SKB-264), PF-06664178, anetumab ravtansine (BAY 94-9343), BMS-986148, DMOT4039A, RC88, lifastuzumab vedotin (DNIB0600A), upifitamab rilsodotin (ABBV-181), ZW220, DMUC4064A, and sofituzumab vedotin (DMUC5754A). The ADCs hold significant potential to reshape the treatment landscape for ovarian cancer by providing targeted therapeutic options. Further research is required to optimize patient selection, address resistance mechanisms, and improve safety profiles.

8 days ago

Review • Journal

MUC4 (Mucin 4, Cell Surface Associated)

Enhertu (fam-trastuzumab deruxtecan-nxki) • Elahere (mirvetuximab soravtansine-gynx) • budigalimab (ABBV-181) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan) • anetumab ravtansine (BAY 94-9343) • upifitamab rilsodotin (XMT-1536) • RG7600 • lifastuzumab vedotin (DNIB0600A) • RG7882 • ZW220 • BMS-986148

TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=744, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Jun 2026 --> Sep 2026

9 days ago

Enrollment closed • Trial completion date • Trial primary completion date

cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)

12d

Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan. (PubMed, Ann Pharmacother)

Dato-DXd offers a promising treatment option for heavily pretreated patients with HR+/HER2- breast cancer and EGFR-mutant NSCLC, providing meaningful clinical benefit with a manageable safety profile. Optimal sequencing and positioning within the rapidly shifting ADC landscape requires further investigation.

12 days ago

Review • Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)

EGFR mutation • HR positive • HER-2 negative • HR positive + HER-2 negative

docetaxel • Datroway (datopotamab deruxtecan-dlnk)

16d

ICARUS-LUNG01: Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=100, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial primary completion date: Sep 2025 --> Apr 2028

16 days ago

Trial primary completion date

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRAF mutation • RET mutation • MET mutation • NTRK fusion

Datroway (datopotamab deruxtecan-dlnk)

16d

TB06: A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer (clinicaltrials.gov)

P3, N=100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

16 days ago

Enrollment open

Datroway (datopotamab deruxtecan-dlnk)

18d

CERTIS1: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov)

P1/2, N=695, Recruiting, AstraZeneca | Trial completion date: Apr 2027 --> Aug 2027 | Trial primary completion date: Apr 2027 --> Aug 2027

18 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • HRD (Homologous Recombination Deficiency) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)

HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation

temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574

18d

CLN-619-001: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=440, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting

18 days ago

Enrollment closed

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • CLN-619

23d

DIAMOND: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)

P2, N=140, Recruiting, Queen Mary University of London | Not yet recruiting --> Recruiting

23 days ago

Enrollment open

PD-L1 IHC 22C3 pharmDx

Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk)

23d

Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. (PubMed, Cancer Chemother Pharmacol)

There are differences in pharmacological effects, efficacy, and incidence of adverse events among sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan. For patients with EGFR-mutated progression after targeted therapy or driver gene negative advanced non-small cell lung cancer, the individualized optimization of TROP2 ADCs treatment can obtain the greatest benefit.

23 days ago

Review • Journal • IO biomarker

EGFR (Epidermal growth factor receptor)

EGFR mutation

Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov)

P3, N=644, Active, not recruiting, AstraZeneca | Trial primary completion date: Dec 2025 --> Aug 2025

1 month ago

Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)

PD-L1 expression • PD-L1 negative

carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan-dlnk)

Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer. (PubMed, Ann Med Surg (Lond))

With better efficacy than conventional treatments, it offers a possible alternative for individuals who have not responded to previous endocrine or chemotherapy therapies. This manuscript reviews the mechanisms of action, clinical efficacy, safety profiles, and trials of Dato-DXd and T-DXd, highlighting their transformative potential and positioning in current breast cancer treatment algorithms.

1 month ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative • EGFR positive

Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk)

2ms

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM (clinicaltrials.gov)

P2, N=60, Recruiting, Brown University | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

dexamethasone • Datroway (datopotamab deruxtecan-dlnk)